HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
J9315 | Romidepsin | Istodax | 1 mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2009 | Jan 1, 2011 | Sep 27, 2021 | No Longer Used | |
Inavolisib | Itovebi | 3mg, 9mg | Chemotherapy | Enzyme Inhibitor | PI3K⍺ | Yes | 2024 | In Use | ||||
Inovolisib | Itovebi | 3mg, 9mg | Chemotherapy | Enzyme Inhibitor | PI3K⍺ | Yes | 2024 | In Use | ||||
J9207 | ixabepilone | Ixempra | 1mg | Chemotherapy | Antitumor Antibiotic | Epothilones | No | 2007 | Jan 1, 2009 | In Use | ||
C9240 | ixabepilone | Ixempra | 1mg | Chemotherapy | Antitumor Antibiotic | Epothilones | No | 2007 | Jan 1, 2008 | Dec 31, 2013 | No Longer Used | |
NA | Ruxolitinib | Jakafi | 20 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 5 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 10 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 15 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Pirtobrutinib | Jaypirca | Multiple | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Yes | 2023 | In Use | |||
C9064 | Mitomycin pyelocalyceal instillation | Jelmyto | 1mg | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/Mitomycin | No | 2020 | Oct 1, 2020 | Jan 1, 2021 | No Longer Used | |
J9281 | Mitomycin Pyelocalyceal Instillation | Jelmyto | 1mg | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/Mitomycin | No | 2020 | Jan 1, 2021 | In Use | ||
J9272 | Dostarlimab-gxly | Jemperli | 10mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2021 | Jan 26, 2022 | In Use | ||
NA | Dostarlimab | Jemperli | 50mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | Yes | 2021 | In Use | |||
C9082 | Dostarlimab-gxly | Jemperli | 100mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2021 | Sep 27, 2021 | Jan 26, 2022 | No Longer Used | |
C9276 | Cabazitaxel | Jevtana | 1 mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2010 | Jan 1, 2011 | Dec 31, 2011 | No Longer Used | |
J9043 | Cabazitaxel | Jevtana | 1 mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2010 | Jan 1, 2012 | In Use | ||
Q5136 | Denosumab-bbdz | Jubbonti/Wyost | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2024 | Sep 11, 2024 | In Use | ||
J8611 | Methotrexate (jylamvo) | Jylamvo | 2.5mg | Chemotherapy | Antimetabolite | Folic Acid Analog | Yes | 2023 | Jun 10, 2024 | In Use | ||
C9131 | Ado-Trastuzumab Emtansine | Kadcyla | 1mg | Immunotherapy | Drug Antibody Conjugate | HER2 | No | 2013 | Jul 1, 2013 | Dec 31, 2013 | No Longer Used | |
J9354 | Ado-Trastuzumab Emtansine | Kadcyla | 1mg | Immunotherapy | Drug Antibody Conjugate | HER2 | No | 2013 | Jan 1, 2014 | In Use | ||
Q5117 | Trastuzumab-anns | Kanjinti | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2019 | Oct 1, 2019 | In Use | ||
J7684 | Triamcinolone | Kenalog Aristocort | 1 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1960 | Jan 1, 2000 | In Use | ||
J3301 | Triamcinolone | Kenalog, Aristocort | 10 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1960 | Jan 1, 1991 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.